Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bayer May Pay Trius Up to $94 Million for Torezolid Antibiotic

Bayer AG agreed to pay Trius Therapeutics Inc. $25 million upfront for collaboration rights to the U.S. biotechnology company’s skin-infection antibiotic torezolid outside the U.S., Canada and Europe.

Bayer will contribute to global development costs for the experimental drug and may pay Trius as much as $69 million if the medicine meets certain development, regulatory and commercial goals, the Leverkusen, Germany-based company said in a statement today. Trius of San Diego, California, will also get double-digit royalties on net sales, Bayer said.

Torezolid is in the final phase of clinical development before U.S. and European Union regulatory approval and is expected to compete with Pfizer Inc.’s Zyvox.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.